블로그
-
Eng.
I'm supposed to take a test, OPIc, on 2nd September. My current grade is IM1. It's somehow low.
blog.naver.com · 2021.08.25
-
NSS 기반으로 한 물리적 방호체계, 시정조치 및 취약점 식별: HARI 사례
Agdal, Morocco, "Physical Protection System, Corrective Actions, and Weaknesses Identification Based on IAEA의 NSS(Nuclear Security Series)를 기반으로 HARI(Hypothetical Atomic Research Institute)에 있는 MTR(Material Test
blog.naver.com · 2021.07.21
-
Force on Force(FOF)에 기반한 물리적 방호 시스템(PPS)의 3차원 모델 및 시뮬레이션
본 내용은 IEEE Access 에 2021년 5월 3일에 발표된 "Using 3D Model and Simulation to Support the Force-on-Force Test
blog.naver.com · 2021.07.15
-
워로봇 테스트서버에서 게임하고 타이폰 받자!
[워로봇 공지 내용] Commanders, we announce additional test session of War Robots Remastered for Android and server will be open on: 12/29 10:00-13:00, 19:0.......
blog.naver.com · 2020.12.30
-
The life-changing exam
pandemic Published duration 6 hours ago Share page About sharing Related Topics Coronavirus pandemic On The Suneung, an abbreviation for College Scholastic Ability Test (CSAT) in Korean, is an eight-hour examination
blog.naver.com · 2020.12.03
-
Python - Other test concepts
*White-box testing (=clear-box or transparent testing) : a test relies on the test creators knowledge of the software being tested to construct the test cases.
blog.naver.com · 2020.08.11
-
Visual AI - FRVT of NIST
Face recognition vendor test - Face recognition technology has been developed by competition of a number of vendors related on artificial intelligence industry.
blog.naver.com · 2020.08.25
-
과거시제 및 환불
it doesn't fit me 나 블라우스 새로 샀는데 말야 안맞아 take it back ,then 그럼 도로 갔다 줘 i saw you yesterday i did well on the test i didn't 나 그때 안했어~~~ 바꿔주세요 환불해주세요 can i exchange this for a new one?
blog.naver.com · 2020.07.30
-
관세청 진단키트 수출 잠정치 5월
COVID-19 Test kits Diagnostic reagents based on polymerase chain reaction (PCR) nucleic acid test 3822.00 COVID-19 Test kits Diagnostic reagents based on immunological reactions 3002.15 기존 셀트리온헬스케어 수출금액과 중복되는
blog.naver.com · 2020.06.01
-
[FDA, 200616] 키트루다, 고형암 환자 대상 허가
TMB-H 고형암 환자 대상 허가 - ORR, DoR (The main efficacy outcome) - ORR 29%, CR 4%, PR 25%. mDoR not reached On burden-high (TMB-H) [≥10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test
blog.naver.com · 2020.06.30
